Site Search

Early stage researchers, life science entrepreneurs, and companies are encouraged to apply starting May 2

New modulators in development by the CF-specific company could provide unique treatment options for the underlying cause of cystic fibrosis for many people with the disease

Today, the Cystic Fibrosis Foundation announced a new award of up to $2 million to Eloxx Pharmaceuticals Inc. to support the global Phase 2 clinical program of ELX-02, a potential therapy to treat people with cystic fibrosis who have nonsense mutations.

Observational study supported by the CF Foundation will monitor real-world experience with Trikafta

Today, the Cystic Fibrosis Foundation announced that it has awarded up to $400,000 to Life Edit Therapeutics Inc. to explore the application of their unique gene editing technology in CF.

White will be the first person living with CF to lead the Board into a new era of CF

Proposed legislation has the potential to revitalize the global marketplace for novel antibiotics, bringing urgently needed medicines for drug-resistant infections to patients.

Study reaffirms the Foundation’s commitment to advance solutions to the growing challenge of antibiotic resistance

Investment will support discovery research of a novel Gene Coding^TM approach that could benefit all people with CF regardless of their mutation